SCHEDULE 13G: Investment Group Discloses 4.99% Stake in Silexion Therapeutics Following Securities Purchase Agreement

A group comprising Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC has disclosed a 4.99% beneficial ownership stake in Silexion Therapeutics Corp. ordinary shares following a recent Securities Purchase Agreement.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G disclosing their beneficial ownership in Silexion Therapeutics Corp.
• As of January 21, 2025, the Reporting Persons collectively beneficially own 209,827 ordinary shares of Silexion Therapeutics Corp., representing approximately 4.99% of the class.
• This ownership consists of 40,741 ordinary shares held directly by Intracoastal Capital LLC and 169,086 ordinary shares issuable upon the exercise of Intracoastal Warrant 2.
• The beneficial ownership percentage is calculated based on 1,849,132 ordinary shares outstanding as of December 31, 2024, plus 2,145,998 ordinary shares in the aggregate issued at the closing of the Securities Purchase Agreement (SPA), 40,741 shares issued upon exercise of Intracoastal Warrant 1, and 169,086 shares issuable upon exercise of Intracoastal Warrant 2.
• The filing indicates that the shares were not acquired for the purpose of changing or influencing the control of the issuer, consistent with a passive investment.
• The beneficial ownership is subject to blocker provisions in the warrants, which prevent exercise beyond certain ownership thresholds (e.g., 9.99% for Warrant 1 and 4.99% for Warrant 2) to avoid triggering certain reporting requirements or control implications.

Sentiment

Score: 6

Explanation: The filing is a standard disclosure of a passive investment, indicating a new investor group has taken a stake in the company. While not overtly positive or negative, it signals external confidence and a capital infusion, which is generally a neutral to slightly positive event for a company.

Positives

• An investment group has taken a significant stake in Silexion Therapeutics, potentially signaling confidence in the company's future.
• The investment was made through a Securities Purchase Agreement, indicating a direct capital infusion into the company.

Negatives

• The beneficial ownership is capped by blocker provisions in the warrants, which may limit the immediate ability of the investors to fully convert their warrants without triggering higher ownership thresholds or additional reporting requirements.

Risks

• The value of the investment is subject to the performance of Silexion Therapeutics Corp.'s ordinary shares.
• The exercise of warrants is subject to blocker provisions, which may limit the investors' ability to increase their stake beyond certain percentages (e.g., 4.99% or 9.99%) without further disclosures or potential control implications.

Future Outlook

The document does not provide any forward-looking statements or guidance from Silexion Therapeutics Corp. It is a disclosure of beneficial ownership by an external party.

Industry Context

This filing indicates an investment in a therapeutics company, which is common in the biotechnology and pharmaceutical sectors where capital raises are frequent for research, development, and commercialization. The investment by a group including an LLC suggests a strategic or financial investment in the sector.

Related Party Transactions

• The filing details a transaction (Securities Purchase Agreement and warrant issuance) between Silexion Therapeutics Corp. and Intracoastal Capital LLC, which is now a significant shareholder group. This constitutes a related party transaction in the context of the investment.

Stakeholder Impact

• Shareholders: The disclosure of a new significant investor group may be viewed positively, signaling external validation. The issuance of new shares and warrants could lead to dilution, but the capital raised would benefit the company.
• Company (Silexion Therapeutics Corp.): The company has received capital through the Securities Purchase Agreement, which can be used for operations, research, or other strategic initiatives.

Key Dates

Keywords

Silexion Therapeutics Corp, Schedule 13G, beneficial ownership, Mitchell P. Kopin, Daniel B. Asher, Intracoastal Capital LLC, ordinary shares, SEC filing, investment, warrants, equity stake, Securities Purchase Agreement